Table 3

Logistic regression analysis concerning age, gender, renal function and medications in relation to the population with HF diagnoses and the population with no diagnosis of HF and BNP > 100 ng/L
Variable HF diagnoses (n = 66) No HF diagnoses and BNP > 100 ng/L (n = 154) p-value OR CI 95% for OR
Age (years) 86.8 ± 5.6 (n = 66) 87.0 ± 6.0 (n = 66) 0.82 1.02 0.94-1.08
Male sex n (%) 20 (30.3) 44 (28.6) 0.91 0.96 0.44-2.10
eGFR (ml/min/1.73 m2) 35.9 ± 16.4 (n = 62) 42.1 ± 15.4 (n = 152) 0.27 0.99 0.96-1.01
ACE inhibitors/ARBs 33 (50) 23 (14.9) <0.001 11.27 3.14-40.41
Beta-blockers 39 (59.1) 70 (45.5) 0.99 1.00 0.48-2.08
Spironolactone 10 (15.2) 8 (5.2) 0.04 3.55 1.08-11.68
Digoxin 16 (24.2) 14 (9.1) 0.31 1.66 0.62-4.43
Furosemide/loop diuretics 50 (75.8) 50 (32.5) <0.001 5.97 2.39-14.92
Loop diuretics with simultaneous ACE inhibitor/ARB treatment 24 (36.4) 35 (22.7) 0.08 0.25 0.05-1.16

Nagelkerke R2 0.34.

Hosmer and Lemeshow test p-value 0.74.

Bolmsjö et al.

Bolmsjö et al. BMC Geriatrics 2013 13:118   doi:10.1186/1471-2318-13-118

Open Data